Background:

In a 2018 descriptive study, cancer incidence in children (age 0–19) in diagnosis years 2003 to 2014 was reported as being highest in New Hampshire and in the Northeast region.

Methods:

Using the Cancer in North America (CiNA) analytic file, we tested the hypotheses that incidence rates in the Northeast were higher than those in other regions of the United States either overall or by race/ethnicity group, and that rates in New Hampshire were higher than the Northeast region as a whole.

Results:

In 2003 to 2014, pediatric cancer incidence was significantly higher in the Northeast than other regions of the United States overall and among non-Hispanic Whites and Blacks, but not among Hispanics and other racial minorities. However, there was no significant variability in incidence in the states within the Northeast overall or by race/ethnicity subgroup. Overall, statistically significantly higher incidence was seen in the Northeast for lymphomas [RR, 1.15; 99% confidence interval (CI), 1.10–1.19], central nervous system neoplasms (RR, 1.12; 99% CI, 1.07–1.16), and neuroblastoma (RR, 1.13; 99% CI, 1.05–1.21).

Conclusions:

Pediatric cancer incidence is statistically significantly higher in the Northeast than in the rest of the United States, but within the Northeast, states have comparable incidence. Differences in cancer subtypes by ethnicity merit further investigation.

Impact:

Our analyses clarify and extend previous reports by statistically confirming the hypothesis that the Northeast has the highest pediatric cancer rates in the country, by providing similar comparisons stratified by race/ethnicity, and by assessing variability within the Northeast.

This article is featured in Highlights of This Issue, p. 1869

In 2018, Siegel and colleagues presented a report titled “Geographic Variation in Pediatric Cancer Incidence – United States, 2003–2014”, reporting that pediatric cancer incidence rates were highest in the Northeast and, by state, rates were “highest in New Hampshire [205.5 (per million per year)], DC (194.0), and New Jersey (192.3) and lowest in South Carolina (149.3) and Mississippi (145.2)” (1). The publication drew attention in New Hampshire where a pediatric cancer cluster and concerns about environmental pollution had received considerable media coverage (2, 3). However, in that descriptive study, because no comparisons were formally tested, the importance of these findings was unclear. The purpose of this paper is to assess whether the Northeast region and New Hampshire are outliers in pediatric cancer incidence in the United States by testing the hypotheses that rates in the Northeast were higher than those in each of other three regions of the United States either overall or by race/ethnic group, or that rates in New Hampshire were higher than the Northeast region as a whole.

The Cancer in North America (CiNA) analytic file for researchers (4) certified by the North American Association of Central Cancer Registries (NAACCR) (5), was used to evaluate pediatric (ages 0–19 years) cancer incidence in the United States (US) during 2003 to 2014, the period reported by Siegel and colleagues (1) Using age-standardized cancer incidence and rate ratios, we compared the individual states of the Northeast region (Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania Rhode Island, and Vermont) with the Northeastern region as a whole to identify outlier states, and we compared the Northeast with other United States Census regions, both overall and by race/ethnicity.

Due to substantial variation in population distributions by race/ethnicity, with minorities comprising from 7% (Vermont) to 47% (New York) of state populations in the Northeast region (Supplementary Fig. S1), we conducted separate analyses for each racial/ethnic population to calculate rate ratios comparing the Northeast with its constituent states, and to compare the Northeast with other US regions and the US as a whole.

All analyses were conducted using the Surveillance, Epidemiology, and End Results Program (SEER) statistical software package SEER*Stat version 8.3.9 (6). SEER*Stat automatically suppressed cell sizes of <6 following NAACCR's guidelines for data quality assurance (7). Race/ethnicity was defined using a combination of race and ethnicity variables provided in the CiNA data set, 1) race recode (White, Black, American Indian/Alaska Native (AIAN), Asian/Pacific Islander (API), Unknown) and 2) Origin Recode NAACCR Hispanic Identification Algorithm (8) (Hispanic, non-Hispanic) to create the race/ethnicity variable for analysis with defined values of non-Hispanic White, non-Hispanic Black, non-Hispanic AIAN, non-Hispanic API and Hispanic (all races) (9). Overall case counts included cases for which either race or ethnicity was unknown.

States can only contribute data to CiNA for years in which they meet criteria for high quality incidence data (10). Some data were excluded from the CiNA analytic file because of lack of permission from the state (Kansas) or failure to meet inclusion quality criteria during diagnosis years 2003 to 2014 [Nevada (1)]; 2003 data were excluded for data quality reasons for Mississippi and Tennessee. Because data from California and Washington states were included, data from the smaller regional registries within these states were excluded to avoid double counting (Fig. 1; ref. 5). Pediatric cases were selected from the “age recode with < 1 years olds” variable including 0–19 years age groups for the diagnosis years 2003 to 2014 using the International Classification of Childhood Cancer (ICCC) definition (11). Patients were included if tumor behavior was coded as “malignant”, “only malignant” in International Classification of Diseases for Oncology, 3rd edition (ICD-O-3) (12), malignant 2010+ cases” (6) and with one primary only or the first of two or more primaries were included. Cases from death certificate or autopsy reporting sources were excluded (Fig. 1). We assessed 12 categories and 47 subtypes of invasive cancer defined by the ICCC as well as pediatric nonmalignant brain tumors. Pediatric brain tumors were selected from the CiNA data set using the primary ICD-O-3 site codes C70.0 – C72.9 and C75.1 – C75.3 with benign or borderline malignant behavior (ICD-O-3 behavior code of /0 and /1); the analysis timeframe for these tumors was 2004 to 2014 based on the start date for data collection relative to benign or borderline malignant behavior nationally in 2004. For validation, case counts were compared with those reported by Siegel (1), taking into account an expectation of small differences in data selection criteria and the accrual of additional cases in the intervening years.

Figure 1.

Derivation of pediatric (0–19 years) cancer cases.

Figure 1.

Derivation of pediatric (0–19 years) cancer cases.

Close modal

The study protocol was approved by the Institutional Review Board of the North American Association of Central Cancer Registries.

Statistical measures

Incidence rates in the four US regions (Northeast, Midwest, South, West) and states within regions, were directly standardized for age to the 2000 US population (19 age groups, Census P25-1130) and presented as rates per 1,000,000 with 95% confidence intervals. Overall incidence rates for United States (“All States”) are also reported. Where the number of cases was smaller than 10 no calculations were made, in accordance with the recommendations of Morris and colleagues relative to data stability (13). Incidence rates were broken down further by race/ethnicity within region and states as non-Hispanic White, non-Hispanic Black, Hispanic, non-Hispanic American Indian/Alaska Native, and non-Hispanic Asian/Pacific Islander. Incidence rate ratios were calculated as the ratio of age-standardized rates to directly compare each region with the Northeastern Region, and compare each state within the Northeast Region with the Northeast as a whole. Standard errors and hence confidence intervals were calculated using Tiwari's method that adjusts for the nonindependence introduced by the overlap between the whole group (e.g., Northeast region) and subgroup (e.g., New Hampshire) (14). The rate ratios were also calculated after stratification by race/ethnicity. To control the type 1 error rate, a Bonferroni correction was used within each race/ethnic group with a modified p value of 0.05/number of tests used to test the composite hypothesis that there is no difference in incidence rates between the Northeast and any of its states or the other three Regions. Specific details of the corrections are shown as footnotes below each table. To make the interpretation of the confidence intervals consistent with the Bonferroni-adjusted p values, the confidence intervals were individually set at 99%. In this way 95% overall confidence level was preserved and therefore when rate ratios and their confidence intervals are presented by race/ethnicity using forest plots, statistical significance at the 5% level after adjustment for multiple testing is indicated by a confidence interval that does not cross the vertical null value line (1.0). Where there were fewer than 10 cases within a state/race/ethnicity group, the rate ratio was not calculated, and this is indicated by ‘NA’. Invasive cancer subtypes and pediatric nonmalignant brain tumors were analyzed in the same way. We used major cancer subtype categories and then presented more granular data for subtypes that showed significant differences within the Northeast region and compared to the rest of the United States as a post-hoc analysis.

Data availability statement

The data are available by application to the North American Association of Central Cancer Registries (4).

The analytic file included 170,039 cases of first primary invasive cancers diagnosed in the United States from 2003 through 2014 in patients aged <20 years (Fig. 1) and 21,419 nonmalignant brain tumors diagnosed from 2004 through 2014. Overall, pediatric invasive cancer incidence was highest among non-Hispanic White children (185.8/million/year), followed by Hispanics (169.2), American Indians/Alaska Natives (149.6), Asian/Pacific Islanders (147.7), and Blacks (134.3) and incidence in the Northeast was significantly higher than the US for Whites and for Blacks (Table 1; Supplementary Table S1). Incidence was significantly lower in the other three regions than the Northeast for all races combined and among non-Hispanic Whites; (Midwest: RR, 0.91; 99% CI, 0.89–0.94, South: RR, 0.90; 99% CI, 0.88–0.92, and West: RR, 0.92; 99% CI, 0.90–0.94). Similar results were seen for non-Hispanic Whites (Midwest: RR, 0.89; 99% CI, 0.87–0.92, South: RR, 0.90; 99% CI, 0.87–0.92, and West: RR, 0.92; 99% CI, 0.89–0.95). There were no significant differences in the comparison of each northeastern state with the Northeast as a whole (Fig. 2). Similar but less precise estimates were seen among non-Hispanic Blacks by region (Midwest: RR, 0.89; 99% CI, 0.83–0.97, South: RR, 0.92; 99% CI, 0.86–0.98, and West: RR, 0.92; 99% CI, 0.84–1.02), and among the larger northeastern states that had sufficient numbers to report. There were no significant regional differences in incidence among Hispanics (Midwest: RR, 0.94; 99% CI, 0.87–1.01, South: RR, 1.03; 99% CI, 0.98–1.09 and West: RR, 0.98; 99% CI, 0.93–1.04), but a significantly lower incidence was seen in Rhode Island than the Northeast as a whole (RR, 0.58; 99% CI, 0.36–0.87). Non-Hispanic Asians/Pacific Islanders in the South experienced significantly higher incidence than their counterparts in the Northeast (RR, 0.87; 99% CI, 0.77–0.98). In contrast, the incidence for non-Hispanic American Indians/Alaska Natives was higher in other regions than the Northeast (Midwest: RR, 1.40; 99% CI, 0.87–2.36, South: RR, 1.50; 99% CI, 0.95–2.49, and West: RR, 1.63; 99% CI, 1.05–2.68).

Table 1.

Age-standardized Incidencea of cancer among persons aged <20 years, by United States Total, US Census Regions, Northeast States, Overallb and by Race/Ethnicity, 2003–2014.

OverallNon-Hispanic WhiteNon-Hispanic BlackHispanic All RacesNon-Hispanic American Indian/Alaska NativeNon-Hispanic Asian/Pacific Islander
Rate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)Count
All States 174.4e (173.6–175.3) 170,039 185.8e (184.7–186.9) 102,838 134.3e (132.4–136.1) 20,119 169.2 (167.5–171.0) 35,989 149.6 (142.1–157.4) 1,510 147.7 (144.3–151.2) 7,189 
Northeast (Reference) 188.8 (186.7–190.9) 32,016 201.8 (199.1–204.5) 21,696 144.8 (139.9–149.7) 3,428 169.8 (165–174.7) 4,744 98.9 (74.6–128.5) 56 154.7 (146.9–162.7) 1,509 
Connecticut 185.9 (177.9–194.1) 2,060 194.7 (184.6–205.3) 1,398 146.3 (126.7–168) 201 177.6 (159.7–196.9) 362 d (d, dd 131.8 (100.9–169.1) 62 
Maine 190.8 (177.1–205.2) 726 194.6 (180.3–209.9) 685 c (c, c9 d (d, dd c (c, c9 213.9 (109.3–377.8) 12 
Massachusetts 181.2 (175.3–187.2) 3,579 194.9 (187.6–202.5) 2,721 124.8 (108.6–142.8) 214 148.3 (134.3–163.3) 413 d (d, dd 141.8 (121.2–165) 169 
New Hampshire 204.0 (190.1–218.6) 812 205.9 (191.3–221.4) 742 119.9 (57.3–221.5) 10 177.9 (120.6–252.7) 31 d (d, dd 155.2 (91.6–246.7) 18 
New Jersey 193.1 (187.9–198.3) 5,322 212.8 (205.5–220.3) 3,183 149.1 (137.7–161.2) 635 177 (166.4–188) 1,050 d (d, dd 148.5 (133.3–165.1) 349 
New York 191.2 (187.7–194.8) 11,441 210.4 (205.4–215.5) 6,714 148.5 (141.2–156.1) 1,543 178.4 (171.2–185.8) 2,319 87.5 (55.4–131.6) 23 168.6 (156.5–181.5) 714 
Pennsylvania 187.8 (183.5–192.2) 7,215 194.6 (189.5–199.8) 5,521 143.9 (134–154.3) 786 154.1 (140.9–168.2) 505 c (c, c9 141.6 (121.1–164.7) 170 
Rhode Island 171.2 (157.1–186.2) 551 197.6 (179.1–217.4) 432 102.2 (67.3–148.7) 27 98.3e (75–126.6) 60 d (d, dd 112.8 (58.1–196.6) 12 
Vermont 165.1 (147.1–184.8) 310 171.4 (152.3–192.2) 300 d (d, dd d (d, dd d (d, dd d (d, dd 
Midwest 172.6e (170.9–174.4) 35,995 180.5e (178.4–182.7) 27,172 129.5e (125.4–133.7) 3,794 158.8 (153.4–164.4) 3,242 138.4 (121.8–156.5) 253 145.3 (136–155) 918 
South 169.4e (168.1–170.7) 62,085 181.3e (179.4–183.2) 34,970 133.1e (130.6–135.5) 11,188 175.2 (172.2–178.2) 13,221 148.3 (135–162.4) 463 134.6e (127.8–141.6) 1,470 
West 173.4e (171.7–175.1) 39,943 185.2e (182.6–187.9) 19,000 133.7 (127.4–140.2) 1,709 166.3 (163.6–169) 14,782 161.2e (149.7–173.2) 738 151.8 (146.7–157.1) 3,292 
OverallNon-Hispanic WhiteNon-Hispanic BlackHispanic All RacesNon-Hispanic American Indian/Alaska NativeNon-Hispanic Asian/Pacific Islander
Rate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)Count
All States 174.4e (173.6–175.3) 170,039 185.8e (184.7–186.9) 102,838 134.3e (132.4–136.1) 20,119 169.2 (167.5–171.0) 35,989 149.6 (142.1–157.4) 1,510 147.7 (144.3–151.2) 7,189 
Northeast (Reference) 188.8 (186.7–190.9) 32,016 201.8 (199.1–204.5) 21,696 144.8 (139.9–149.7) 3,428 169.8 (165–174.7) 4,744 98.9 (74.6–128.5) 56 154.7 (146.9–162.7) 1,509 
Connecticut 185.9 (177.9–194.1) 2,060 194.7 (184.6–205.3) 1,398 146.3 (126.7–168) 201 177.6 (159.7–196.9) 362 d (d, dd 131.8 (100.9–169.1) 62 
Maine 190.8 (177.1–205.2) 726 194.6 (180.3–209.9) 685 c (c, c9 d (d, dd c (c, c9 213.9 (109.3–377.8) 12 
Massachusetts 181.2 (175.3–187.2) 3,579 194.9 (187.6–202.5) 2,721 124.8 (108.6–142.8) 214 148.3 (134.3–163.3) 413 d (d, dd 141.8 (121.2–165) 169 
New Hampshire 204.0 (190.1–218.6) 812 205.9 (191.3–221.4) 742 119.9 (57.3–221.5) 10 177.9 (120.6–252.7) 31 d (d, dd 155.2 (91.6–246.7) 18 
New Jersey 193.1 (187.9–198.3) 5,322 212.8 (205.5–220.3) 3,183 149.1 (137.7–161.2) 635 177 (166.4–188) 1,050 d (d, dd 148.5 (133.3–165.1) 349 
New York 191.2 (187.7–194.8) 11,441 210.4 (205.4–215.5) 6,714 148.5 (141.2–156.1) 1,543 178.4 (171.2–185.8) 2,319 87.5 (55.4–131.6) 23 168.6 (156.5–181.5) 714 
Pennsylvania 187.8 (183.5–192.2) 7,215 194.6 (189.5–199.8) 5,521 143.9 (134–154.3) 786 154.1 (140.9–168.2) 505 c (c, c9 141.6 (121.1–164.7) 170 
Rhode Island 171.2 (157.1–186.2) 551 197.6 (179.1–217.4) 432 102.2 (67.3–148.7) 27 98.3e (75–126.6) 60 d (d, dd 112.8 (58.1–196.6) 12 
Vermont 165.1 (147.1–184.8) 310 171.4 (152.3–192.2) 300 d (d, dd d (d, dd d (d, dd d (d, dd 
Midwest 172.6e (170.9–174.4) 35,995 180.5e (178.4–182.7) 27,172 129.5e (125.4–133.7) 3,794 158.8 (153.4–164.4) 3,242 138.4 (121.8–156.5) 253 145.3 (136–155) 918 
South 169.4e (168.1–170.7) 62,085 181.3e (179.4–183.2) 34,970 133.1e (130.6–135.5) 11,188 175.2 (172.2–178.2) 13,221 148.3 (135–162.4) 463 134.6e (127.8–141.6) 1,470 
West 173.4e (171.7–175.1) 39,943 185.2e (182.6–187.9) 19,000 133.7 (127.4–140.2) 1,709 166.3 (163.6–169) 14,782 161.2e (149.7–173.2) 738 151.8 (146.7–157.1) 3,292 

aRates are per 1,000,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25–1130) standard; Confidence intervals (Tiwari, R.C. [2006] method) are 95% for rates.

bOverall case counts include 2,394 (1.4%) unknown race/ethnicity (non-Hispanic unknown: N = 2,354; unknown all races: N = 40).

cAge standardized rate not calculated for counts < 10. Counts < 10 are italicized (Morris, JK, 2018).

dStatistics not displayed due to fewer than 6 cases to preserve confidentiality.

eThe age-standardized rate is significantly different to the rate for Northeast after adjusting for multiple testing, (P < 0.001, overall significance level).

Figure 2.

RRs and 99% CIs† of age-standardized childhood cancer incidence rates for states and regions compared with Northeast (NE) among all races - overall§ (A); RR and 99% CIs for states and regions compared with NE among non-Hispanic Black pediatric cancer cases (B); RR and 99% CIs for states and regions compared with NE among Non-Hispanic White pediatric cancer cases (C); RR and 99% CIs for states and regions compared with NE among Hispanic pediatric cases (D); RR and 99% CIs for states and regions compared with NE among Non-Hispanic American Indian/Alaska Native (E); RR and 99% CIs for states and regions compared with NE among Non-Hispanic Asian/Pacific Islander pediatric cases (F).

Figure 2.

RRs and 99% CIs† of age-standardized childhood cancer incidence rates for states and regions compared with Northeast (NE) among all races - overall§ (A); RR and 99% CIs for states and regions compared with NE among non-Hispanic Black pediatric cancer cases (B); RR and 99% CIs for states and regions compared with NE among Non-Hispanic White pediatric cancer cases (C); RR and 99% CIs for states and regions compared with NE among Hispanic pediatric cases (D); RR and 99% CIs for states and regions compared with NE among Non-Hispanic American Indian/Alaska Native (E); RR and 99% CIs for states and regions compared with NE among Non-Hispanic Asian/Pacific Islander pediatric cases (F).

Close modal

Incidence in the United States overall was highest for leukemias (45.9 per million), followed by central nervous system (CNS; 31.2) and lymphomas (26.4; Table 2; Supplementary Tables S2A–S2F). Incidence rates in non-Hispanic White children in the Northeast were significantly higher than the United States for leukemias (RR, 1.07; 99% CI, 1.03–1.12), lymphomas (RR, 1.12; 99% CI, 1.07–1.18), CNS neoplasms (RR, 1.10; 99% CI, 1.05–1.15), neuroblastoma (RR, 1.11; 99% CI, 1.01–1.20), and other malignancies (Fig. 3). Within these categories, significantly elevated rates in the Northeast compared with the United States were seen for lymphoid leukemias (RR, 1.09; 99% CI, 1.04–1.14), Hodgkin (RR, 1.16; 99% CI, 1.09–1.24) and non-Hodgkin (RR, 1.14; 99% CI, 1.05–1.25) lymphomas; astrocytomas (RR, 1.12; 99% CI, 1.05–1.19); other gliomas (RR, 1.19; 99% CI, 1.07–1.32; Supplementary Table S2b). In the United States and in the Northeast, there was a more than three-fold higher annual incidence of thyroid cancers among non-Hispanic Whites than non-Hispanic Blacks; among non-Hispanic Whites, thyroid cancer incidence in the Northeast was significantly higher than the United States (RR, 1.33; 99% CI, 1.23–1.44; Supplementary Table S2C).

Table 2.

Comparison of Age-standardized Incidencea,c of Cancer, among Persons Aged <20 years, for Northeast Regionb with the United States by Race/Ethnicity, 2003–2014.

OverallNon-Hispanic WhiteNon-Hispanic Black
Cancer TypeAll States (Population: 968,956,124; Reference)Northeast (Population: 168,302,782)All States (Population: 550,723,012; Reference)Northeast (Population: 106,960,493)All States (Population: 149,189,102; Reference)Northeast (Population: 23,512,857)
ICCC site recode ICD-O-3/WHO 2008Rate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)Count
I Leukemias, myeloproliferative & myelodysplastic diseases 45.9 (45.5–46.4) 44,480 47.2 (46.1–48.2) 7,830 45.6 (45.1–46.2) 24,755 49.0f (47.6–50.4) 5,078 29.7 (28.8–30.5) 4,407 32.0 (29.7–34.4) 747 
II Lymphomas and reticuloendothelial neoplasms 26.4 (26.0–26.7) 25,856 30.2f (29.4–31.0) 5,256 28.1 (27.7–28.6) 15,969 31.6f (30.5–32.6) 3,555 22.6 (21.8–23.3) 3,440 26.0f (24.0–28.1) 634 
III CNS and misc. intracranial and intraspinal neoplasms 31.2 (30.9–31.6) 30,150 34.8f (33.9–35.7) 5,800 35.5 (35.0–36.0) 19,334 38.9f (37.8–40.2) 4,093 24.8 (24.0–25.6) 3,663 26.4 (24.4–28.6) 614 
IV Neuroblastoma and other peripheral nervous cell tumors 8.5 (8.3–8.7) 8,217 9.6f (9.1–10.1) 1,552 10.1 (9.8–10.4) 5,330 11.1f (10.5–11.8) 1,094 7.3 (6.9–7.8) 1,078 7.8 (6.7–9.0) 176 
V Retinoblastoma 3.2 (3.1–3.3) 3,104 3.3 (3.0–3.6) 533 2.9 (2.7–3.0) 1,500 3.0 (2.7–3.4) 293 3.5 (3.2–3.8) 514 3.8 (3.0–4.6) 85 
VI Renal tumors 6.9 (6.7–7.0) 6,633 7.1 (6.7–7.5) 1,151 7.2 (7.0–7.4) 3,843 7.2 (6.6–7.7) 717 8.6 (8.1–9.1) 1,258 8.3 (7.2–9.6) 189 
VII Hepatic tumors 2.3 (2.2–2.4) 2,279 2.5 (2.3–2.8) 419 2.3 (2.2–2.4) 1,226 2.4 (2.1–2.7) 240 1.7 (1.5–2.0) 257 2.0 (1.5–2.7) 47 
VIII Malignant bone tumors 8.6 (8.4–8.7) 8,358 9.1 (8.7–9.6) 1,575 9.0 (8.8–9.3) 5,096 9.5 (9.0–10.1) 1,065 7.1 (6.6–7.5) 1,072 7.5 (6.5–8.7) 182 
IX Soft tissue and other extraosseous sarcomas 11.7 (11.5–11.9) 11,422 12.5f (11.9–13.0) 2,118 11.8 (11.5–12.1) 6,565 12.7 (12.0–13.4) 1,371 12.6 (12.0–13.2) 1,896 13.7 (12.3–15.3) 327 
X Germ cell & trophoblastic tumors & neoplasms of gonads 11.0 (10.8–11.2) 10,886 10.8 (10.4–11.3) 1,912 10.9 (10.7–11.2) 6,276 11. (10.9–12.2) 1,316 6.2 (5.8–6.6) 942 5.9 (5.0–6.9) 145 
XI Other malignant epithelial neoplasms and melanomas 17.8 (17.6–18.1) 17,709 20.9f (20.3–21.6) 3,738 21.4 (21.0–21.8) 12,403 24.1f (23.2–25.0) 2,798 9.4 (8.9–9.9) 1,448 10.5 (9.3–11.9) 262 
XII Other and unspecified malignant neoplasms 0.7 (0.7–0.8) 706 0.6 (0.5–0.8) 107 0.7 (0.6–0.8) 399 0.6 (0.4–0.7) 62 0.8 (0.6–0.9) 114 d (d, dd 
Not classified by ICCC or in situ+ 0.2 (0.2–0.3) 239 0.1 (0.1–0.2) 25 0.3 (0.2–0.3) 142 0.1f (0.1–0.2) 14 0.2 (0.1–0.3) 30 d (d, de 
OverallNon-Hispanic WhiteNon-Hispanic Black
Cancer TypeAll States (Population: 968,956,124; Reference)Northeast (Population: 168,302,782)All States (Population: 550,723,012; Reference)Northeast (Population: 106,960,493)All States (Population: 149,189,102; Reference)Northeast (Population: 23,512,857)
ICCC site recode ICD-O-3/WHO 2008Rate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)Count
I Leukemias, myeloproliferative & myelodysplastic diseases 45.9 (45.5–46.4) 44,480 47.2 (46.1–48.2) 7,830 45.6 (45.1–46.2) 24,755 49.0f (47.6–50.4) 5,078 29.7 (28.8–30.5) 4,407 32.0 (29.7–34.4) 747 
II Lymphomas and reticuloendothelial neoplasms 26.4 (26.0–26.7) 25,856 30.2f (29.4–31.0) 5,256 28.1 (27.7–28.6) 15,969 31.6f (30.5–32.6) 3,555 22.6 (21.8–23.3) 3,440 26.0f (24.0–28.1) 634 
III CNS and misc. intracranial and intraspinal neoplasms 31.2 (30.9–31.6) 30,150 34.8f (33.9–35.7) 5,800 35.5 (35.0–36.0) 19,334 38.9f (37.8–40.2) 4,093 24.8 (24.0–25.6) 3,663 26.4 (24.4–28.6) 614 
IV Neuroblastoma and other peripheral nervous cell tumors 8.5 (8.3–8.7) 8,217 9.6f (9.1–10.1) 1,552 10.1 (9.8–10.4) 5,330 11.1f (10.5–11.8) 1,094 7.3 (6.9–7.8) 1,078 7.8 (6.7–9.0) 176 
V Retinoblastoma 3.2 (3.1–3.3) 3,104 3.3 (3.0–3.6) 533 2.9 (2.7–3.0) 1,500 3.0 (2.7–3.4) 293 3.5 (3.2–3.8) 514 3.8 (3.0–4.6) 85 
VI Renal tumors 6.9 (6.7–7.0) 6,633 7.1 (6.7–7.5) 1,151 7.2 (7.0–7.4) 3,843 7.2 (6.6–7.7) 717 8.6 (8.1–9.1) 1,258 8.3 (7.2–9.6) 189 
VII Hepatic tumors 2.3 (2.2–2.4) 2,279 2.5 (2.3–2.8) 419 2.3 (2.2–2.4) 1,226 2.4 (2.1–2.7) 240 1.7 (1.5–2.0) 257 2.0 (1.5–2.7) 47 
VIII Malignant bone tumors 8.6 (8.4–8.7) 8,358 9.1 (8.7–9.6) 1,575 9.0 (8.8–9.3) 5,096 9.5 (9.0–10.1) 1,065 7.1 (6.6–7.5) 1,072 7.5 (6.5–8.7) 182 
IX Soft tissue and other extraosseous sarcomas 11.7 (11.5–11.9) 11,422 12.5f (11.9–13.0) 2,118 11.8 (11.5–12.1) 6,565 12.7 (12.0–13.4) 1,371 12.6 (12.0–13.2) 1,896 13.7 (12.3–15.3) 327 
X Germ cell & trophoblastic tumors & neoplasms of gonads 11.0 (10.8–11.2) 10,886 10.8 (10.4–11.3) 1,912 10.9 (10.7–11.2) 6,276 11. (10.9–12.2) 1,316 6.2 (5.8–6.6) 942 5.9 (5.0–6.9) 145 
XI Other malignant epithelial neoplasms and melanomas 17.8 (17.6–18.1) 17,709 20.9f (20.3–21.6) 3,738 21.4 (21.0–21.8) 12,403 24.1f (23.2–25.0) 2,798 9.4 (8.9–9.9) 1,448 10.5 (9.3–11.9) 262 
XII Other and unspecified malignant neoplasms 0.7 (0.7–0.8) 706 0.6 (0.5–0.8) 107 0.7 (0.6–0.8) 399 0.6 (0.4–0.7) 62 0.8 (0.6–0.9) 114 d (d, dd 
Not classified by ICCC or in situ+ 0.2 (0.2–0.3) 239 0.1 (0.1–0.2) 25 0.3 (0.2–0.3) 142 0.1f (0.1–0.2) 14 0.2 (0.1–0.3) 30 d (d, de 
HispanicNon-Hispanic American Indian/Alaska NativeNon-Hispanic Asian/Pacific Islander
Cancer TypeAll States (Population: 210,772,149; Reference)Northeast (Population: 27,626,954)All States (Population: 10,021,360; Reference)Northeast (Population: 56,162)All States (Population: 48,250,501; Reference)Northeast (Population: 9,640,856)
ICCC site recode ICD-O-3/WHO 2008Rate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)Count
I Leukemias, myeloproliferative & myelodysplastic diseases 56.2 (55.2–57.2) 12,151 50.5f (47.9–53.2) 1,421 43.8 (39.8–48.1) 436 25.3 (13.8–42.4) 14 45.6 (43.7–47.5) 2,225 47.9 (43.7–52.5) 469 
II Lymphomas and reticuloendothelial neoplasms 23.6 (22.9–24.2) 4,864 28.0f (26.1–30.1) 766 18.2 (15.6–21.0) 185 d (d, d8 22.0 (20.6–23.3) 1,060 22.7 (19.8–25.9) 218 
III CNS and misc. intracranial and intraspinal neoplasms 24.9 (24.3–25.6) 5,364 26.5 (24.6–28.5) 738 26.4 (23.3–29.8) 263 17.7 (8.5–32.7) 10 22.2 (20.9–23.5) 1,073 23.0 (20.0–26.2) 223 
IV Neuroblastoma and other peripheral nervous cell tumors 5.5 (5.2–5.8) 1,290 6.0 (5.2–7.0) 181 6.0 (4.6–7.8) 60 d (d, de 6.8 (6.1–7.6) 341 6.9 (5.4–8.7) 72 
V Retinoblastoma 3.5 (3.3–3.8) 839 3.3 (2.7–4.0) 102 2.8 (1.9–4.1) 28 d (d, de 3.4 (2.9–3.9) 169 3.8 (2.7–5.2) 40 
VI Renal tumors 5.3 (5.0–5.6) 1,199 6.1 (5.3–7.1) 180 6.5 (5.0–8.3) 64 d (d, de 3.5 (3.0–4.1) 175 3.6 (2.5–4.9) 36 
VII Hepatic tumors 2.6 (2.4–2.8) 594 2.8 (2.3–3.5) 84 3.1 (2.1–4.4) 31 d (d, de 2.9 (2.4–3.4) 143 3.7 (2.6–5.1) 38 
VIII Malignant bone tumors 8.4 (8.0–8.8) 1,691 8.8 (7.7–10.0) 236 7.1 (5.5–8.9) 72 d (d, de 7.2 (6.5–8.0) 345 7.7 (6.0–9.7) 72 
IX Soft tissue and other extraosseous sarcomas 10.8 (10.4–11.3) 2,273 11.0 (9.8–12.3) 305 11.0 (9.1–13.3) 112 d (d, de 8.4 (7.6–9.3) 409 8.0 (6.3–10.0) 78 
X Germ cell & trophoblastic tumors & neoplasms of gonads 14.2 (13.7–14.7) 2,875 11.1f (9.9–12.4) 306 9.5 (7.8–11.6) 100 d (d, de 11.7 (10.7–12.7) 566 11.3 (9.3–13.6) 110 
XI Other malignant epithelial neoplasms and melanomas 13.3 (12.8–13.8) 2,659 14.9 (13.5–16.5) 406 13.8 (11.7–16.3) 145 d (d, de 13.4 (12.4–14.5) 649 15.0 (12.6–17.7) 143 
XII Other and unspecified malignant neoplasms 0.7 (0.6–0.8) 141 0.5 (0.3–0.8) 14 d (d, d8 d (d, de 0.5 (0.3–0.8) 25 d (d, d9 
Not classified by ICCC or in situ+ 0.2 (0.2–0.3) 49 d (d, de d (d, d6 d (d, de d (d, d9 d (d, de 
HispanicNon-Hispanic American Indian/Alaska NativeNon-Hispanic Asian/Pacific Islander
Cancer TypeAll States (Population: 210,772,149; Reference)Northeast (Population: 27,626,954)All States (Population: 10,021,360; Reference)Northeast (Population: 56,162)All States (Population: 48,250,501; Reference)Northeast (Population: 9,640,856)
ICCC site recode ICD-O-3/WHO 2008Rate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)Count
I Leukemias, myeloproliferative & myelodysplastic diseases 56.2 (55.2–57.2) 12,151 50.5f (47.9–53.2) 1,421 43.8 (39.8–48.1) 436 25.3 (13.8–42.4) 14 45.6 (43.7–47.5) 2,225 47.9 (43.7–52.5) 469 
II Lymphomas and reticuloendothelial neoplasms 23.6 (22.9–24.2) 4,864 28.0f (26.1–30.1) 766 18.2 (15.6–21.0) 185 d (d, d8 22.0 (20.6–23.3) 1,060 22.7 (19.8–25.9) 218 
III CNS and misc. intracranial and intraspinal neoplasms 24.9 (24.3–25.6) 5,364 26.5 (24.6–28.5) 738 26.4 (23.3–29.8) 263 17.7 (8.5–32.7) 10 22.2 (20.9–23.5) 1,073 23.0 (20.0–26.2) 223 
IV Neuroblastoma and other peripheral nervous cell tumors 5.5 (5.2–5.8) 1,290 6.0 (5.2–7.0) 181 6.0 (4.6–7.8) 60 d (d, de 6.8 (6.1–7.6) 341 6.9 (5.4–8.7) 72 
V Retinoblastoma 3.5 (3.3–3.8) 839 3.3 (2.7–4.0) 102 2.8 (1.9–4.1) 28 d (d, de 3.4 (2.9–3.9) 169 3.8 (2.7–5.2) 40 
VI Renal tumors 5.3 (5.0–5.6) 1,199 6.1 (5.3–7.1) 180 6.5 (5.0–8.3) 64 d (d, de 3.5 (3.0–4.1) 175 3.6 (2.5–4.9) 36 
VII Hepatic tumors 2.6 (2.4–2.8) 594 2.8 (2.3–3.5) 84 3.1 (2.1–4.4) 31 d (d, de 2.9 (2.4–3.4) 143 3.7 (2.6–5.1) 38 
VIII Malignant bone tumors 8.4 (8.0–8.8) 1,691 8.8 (7.7–10.0) 236 7.1 (5.5–8.9) 72 d (d, de 7.2 (6.5–8.0) 345 7.7 (6.0–9.7) 72 
IX Soft tissue and other extraosseous sarcomas 10.8 (10.4–11.3) 2,273 11.0 (9.8–12.3) 305 11.0 (9.1–13.3) 112 d (d, de 8.4 (7.6–9.3) 409 8.0 (6.3–10.0) 78 
X Germ cell & trophoblastic tumors & neoplasms of gonads 14.2 (13.7–14.7) 2,875 11.1f (9.9–12.4) 306 9.5 (7.8–11.6) 100 d (d, de 11.7 (10.7–12.7) 566 11.3 (9.3–13.6) 110 
XI Other malignant epithelial neoplasms and melanomas 13.3 (12.8–13.8) 2,659 14.9 (13.5–16.5) 406 13.8 (11.7–16.3) 145 d (d, de 13.4 (12.4–14.5) 649 15.0 (12.6–17.7) 143 
XII Other and unspecified malignant neoplasms 0.7 (0.6–0.8) 141 0.5 (0.3–0.8) 14 d (d, d8 d (d, de 0.5 (0.3–0.8) 25 d (d, d9 
Not classified by ICCC or in situ+ 0.2 (0.2–0.3) 49 d (d, de d (d, d6 d (d, de d (d, d9 d (d, de 

aRates are per 1,000,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25–1130) standard; Confidence intervals (Tiwari, R.C. [2006] method) are 95% for rates.

bNortheast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont.

cIncidence data are compiled from cancer registries that meet the data quality criteria for all years 2003–2014 (covering >99% of the U.S. population). Nevada is excluded; Kansas not included and diagnosis year 2003 not included for Mississippi and Tennessee. Registry-specific data quality information is available from NAACCR (5).

dAge standardized rate not calculated for counts < 10. Counts < 10 are italicized.

eStatistics not displayed due to fewer than 6 cases to preserve confidentiality.

fThe age-standardized rate is significantly different to the rate for Northeast after adjusting for multiple testing, (P < 0.01, overall significance level).

+Note that in this study, we excluded in situs but have retained the ICCC site recode nomenclature.

Figure 3.

Pediatric cancer types†, * RRs and 99% CIs β of age-standardized incidence rates for the Northeast (NE) compared with the United States (US) for all races - overall§ (A); RR and 99% CIs for NE pediatric cancer types compared with United States among non-Hispanic Black (B); RR and 99% CIs for NE pediatric cancer types compared with United States among non-Hispanic White (C); RR and 99% CIs for NE pediatric cancer types compared with United States among Hispanic (D); RR and 99% CIs for NE pediatric cancer types compared with United States among Non-Hispanic American Indian/Alaska Native (E); RR and 99% CIs for NE pediatric cancer types compared with United States among non-Hispanic Asian/Pacific Islander (F).

Figure 3.

Pediatric cancer types†, * RRs and 99% CIs β of age-standardized incidence rates for the Northeast (NE) compared with the United States (US) for all races - overall§ (A); RR and 99% CIs for NE pediatric cancer types compared with United States among non-Hispanic Black (B); RR and 99% CIs for NE pediatric cancer types compared with United States among non-Hispanic White (C); RR and 99% CIs for NE pediatric cancer types compared with United States among Hispanic (D); RR and 99% CIs for NE pediatric cancer types compared with United States among Non-Hispanic American Indian/Alaska Native (E); RR and 99% CIs for NE pediatric cancer types compared with United States among non-Hispanic Asian/Pacific Islander (F).

Close modal

The pattern for non-Hispanic Black children resembled that for Whites but with less precision in the estimates due to smaller numbers. However, Hispanic children in the Northeast had a different pattern than their counterparts in the United States as a whole, with significantly lower incidence of leukemias (RR, 0.90; 99% CI, 0.83–0.96; Fig. 3), specifically lymphoid leukemias (RR, 0.84; 99% CI, 0.77–0.91; Supplementary Table S2D) and germ cell tumors (RR, 0.78; 99% CI, 0.67–0.91; Fig. 3), specifically malignant gonadal germ cell tumors (RR, 0.69; 99% CI, 0.56–0.83; Supplementary Table S2d). Hispanics had significantly higher incidence of lymphomas (RR, 1.19; 99% CI, 1.07–1.31; Fig. 3) as well as the renal tumor subcategory, renal carcinoma (RR, 2.04; 99% CI, 1.04–3.72; Supplementary Table S2D). Asian/Pacific Islanders in the Northeast had incidence rates of the cancer subtypes that were comparable with the United States as a whole (Fig. 3; Supplementary Table S2F).

The incidence of nonmalignant brain tumors was significantly higher in the Northeast than the country overall, and for non-Hispanic Whites and for Hispanics; rates for non-Hispanic Blacks and non-Hispanic Asian/Pacific Islanders were higher in the Northeast but not significantly different than the United States. Incidence by state within the Northeast varied widely from 17.4 to 33.0 per million per year (Table 3).

Table 3.

Age-standardized incidencea of non-malignant brain tumors among persons aged <20 Years, by United States (US), US Census Regions, Northeast States, Overall and by Race/Ethnicity, 2004b–2014.

OverallNon-Hispanic WhiteNon-Hispanic BlackHispanic All RacesNon-Hispanic American Indian/Alaska NativeNon-Hispanic Asian/Pacific Islander
Rate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)Count
All states 23.8e (23.5–24.1) 21,419 25.3e (24.8–25.7) 12,970 19.4 (18.7–20.2) 2,711 22.3e (21.7–23.0) 4,284 25.4 (22.3–28.8) 239 16.3 (15.2–17.5) 732 
Northeast (Reference) 26.9 (26.1–27.8) 4,240 27.3 (26.3–28.3) 2,741 21.4 (19.5–23.4) 468 28.2 (26.2–30.4) 717 c (c, c8 20.1 (17.2–23.2) 178 
Connecticut 22.1e (19.3–25.1) 228 23.1 (19.6–27.0) 156 11.6 (6.5–19.2) 15 22.4 (16.1–30.3) 42 c (c, cd c (c, cc 
Maine 17.1e (13.1–22.1) 61 17.4e (13.1–22.6) 57 c (c, cd c (c, cd c (c, cd c (c, cd 
Massachusetts 21.1e (19.0–23.3) 389 23.5 (21.0–26.3) 309 18.4 (12.3–26.5) 29 11.0e (7.3–15.9) 28 c (c, cd c (c, cc 
New Hampshire 27.1 (22.1–32.9) 104 26.4 (21.3–32.5) 92 c (c, cd c (c, cd c (c, cd c (c, cd 
New Jersey 26.9 (24.9–29.0) 682 27.0 (24.4–29.9) 374 21.1 (16.8–26.2) 83 30.6 (26.1–35.6) 165 c (c, cd 19.3 (13.8–26.3) 40 
New York 32.4e (30.9–34.0) 1,786 33.0e (31.0–35.2) 973 25.5 (22.4–28.9) 244 35.3e (32.0–38.8) 416 c (c, cd 24.9 (20.2–30.4) 97 
Pennsylvania 24.4e (22.8–26.0) 882 25.7 (23.8–27.7) 690 17.8 (14.3–21.8) 91 17.2e (12.8–22.7) 51 c (c, cd c (c, cc 
Rhode Island 19.2 (14.5–25.0) 57 20.3 (14.5–27.7) 41 c (c, cd c (c, c9 c (c, cd c (c, cd 
Vermont 28.2 (21.0–37.3) 51 28.9 (21.3–38.4) 49 c (c, cd c (c, cd c (c, cd c (c, cd 
Midwest 22.8e (22.1–23.5) 4,377 23.9e (23.1–24.7) 3,325 18.3 (16.8–20.0) 496 19.2e (17.2–21.4) 347 17.9 (12.0–25.5) 30 14.5 (11.6–18.0) 84 
South 23.1e (22.6–23.7) 7,844 24.7e (23.9–25.4) 4,427 19.0 (18.0–20.0) 1,492 23.1e (22.0–24.3) 1,565 19.0 (14.3–24.6) 56 15.5 (13.1–18.1) 156 
West 23.7e (23.1–24.4) 5,155 26.6 (25.6–27.6) 2,626 21.7 (19.1–24.5) 265 20.7e (19.7–21.7) 1,683 34.2 (28.9–40.2) 148 15.6e (13.9–17.4) 316 
OverallNon-Hispanic WhiteNon-Hispanic BlackHispanic All RacesNon-Hispanic American Indian/Alaska NativeNon-Hispanic Asian/Pacific Islander
Rate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)CountRate (95% CI)Count
All states 23.8e (23.5–24.1) 21,419 25.3e (24.8–25.7) 12,970 19.4 (18.7–20.2) 2,711 22.3e (21.7–23.0) 4,284 25.4 (22.3–28.8) 239 16.3 (15.2–17.5) 732 
Northeast (Reference) 26.9 (26.1–27.8) 4,240 27.3 (26.3–28.3) 2,741 21.4 (19.5–23.4) 468 28.2 (26.2–30.4) 717 c (c, c8 20.1 (17.2–23.2) 178 
Connecticut 22.1e (19.3–25.1) 228 23.1 (19.6–27.0) 156 11.6 (6.5–19.2) 15 22.4 (16.1–30.3) 42 c (c, cd c (c, cc 
Maine 17.1e (13.1–22.1) 61 17.4e (13.1–22.6) 57 c (c, cd c (c, cd c (c, cd c (c, cd 
Massachusetts 21.1e (19.0–23.3) 389 23.5 (21.0–26.3) 309 18.4 (12.3–26.5) 29 11.0e (7.3–15.9) 28 c (c, cd c (c, cc 
New Hampshire 27.1 (22.1–32.9) 104 26.4 (21.3–32.5) 92 c (c, cd c (c, cd c (c, cd c (c, cd 
New Jersey 26.9 (24.9–29.0) 682 27.0 (24.4–29.9) 374 21.1 (16.8–26.2) 83 30.6 (26.1–35.6) 165 c (c, cd 19.3 (13.8–26.3) 40 
New York 32.4e (30.9–34.0) 1,786 33.0e (31.0–35.2) 973 25.5 (22.4–28.9) 244 35.3e (32.0–38.8) 416 c (c, cd 24.9 (20.2–30.4) 97 
Pennsylvania 24.4e (22.8–26.0) 882 25.7 (23.8–27.7) 690 17.8 (14.3–21.8) 91 17.2e (12.8–22.7) 51 c (c, cd c (c, cc 
Rhode Island 19.2 (14.5–25.0) 57 20.3 (14.5–27.7) 41 c (c, cd c (c, c9 c (c, cd c (c, cd 
Vermont 28.2 (21.0–37.3) 51 28.9 (21.3–38.4) 49 c (c, cd c (c, cd c (c, cd c (c, cd 
Midwest 22.8e (22.1–23.5) 4,377 23.9e (23.1–24.7) 3,325 18.3 (16.8–20.0) 496 19.2e (17.2–21.4) 347 17.9 (12.0–25.5) 30 14.5 (11.6–18.0) 84 
South 23.1e (22.6–23.7) 7,844 24.7e (23.9–25.4) 4,427 19.0 (18.0–20.0) 1,492 23.1e (22.0–24.3) 1,565 19.0 (14.3–24.6) 56 15.5 (13.1–18.1) 156 
West 23.7e (23.1–24.4) 5,155 26.6 (25.6–27.6) 2,626 21.7 (19.1–24.5) 265 20.7e (19.7–21.7) 1,683 34.2 (28.9–40.2) 148 15.6e (13.9–17.4) 316 

aRates are per 1,000,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) standard; Confidence intervals (Tiwari, R.C. [2006] method) are 95% for rates.

bNationally, identification of benign brain tumors began in United States cancer registries on 1/1/2004 mandated by Public Law 107, 260, the Benign Brain Tumor Cancer Registries Amendment Act (https://training.seer.cancer.gov/brain/non-malignant/).

cAge standardized rate not calculated for counts < 10. Counts < 10 are italicized.

dStatistics not displayed due to fewer than 6 cases to preserve confidentiality.

eThe age-standardized rate is significantly different to the rate for Northeast after adjusting for multiple testing, (P < 0.01, overall significance level).

Pediatric cancer incidence is significantly higher in the Northeast than other regions of the United States with incidence of 188.8 per million per year compared with 174.4 overall. However, there was no significant variability in incidence in the states within the Northeast region – that is, none of the Northeastern states was identified as an outlier within the region. For example, the incidence in New Hampshire, cited previously as the state with the highest rate, is not statistically distinguishable from other states within the Northeast both overall and when stratified by race. The populations of the Northeast show substantial variation in race/ethnicity distribution: minorities comprise fewer than 10% of the populations of the three most northern states (Maine, New Hampshire, and Vermont) but nearly half of the populations of New York and New Jersey. Because the age-standardized incidence rates vary by more than 38% across racial groups, with lowest rates in non-Hispanic Black children (144.8 per million per year) and highest in non-Hispanic Whites (201.8 per million per year), consideration of race in any regional comparisons is critical. The patterns we see indicate that there are differences in cancer types by race/ethnicity and region. In particular, the higher incidence of certain cancer types in the Northeast than the US were not mirrored in the Hispanic population, and Hispanic children in the Northeast have lower incidence of acute lymphoblastic leukemia (ALL) and germ cell tumors than elsewhere in the country. It has been reported previously that ALL is more common in Hispanics than non-Hispanics at most ages through the lifespan in the United States (15), although some studies in smaller populations within the US have found rates to be comparable (16, 17), perhaps because the category “Hispanic” includes diverse ancestries and therefore diverse genetic and environmental risk factors. In our data, it is unclear why Hispanic children in Rhode Island have lower cancer incidence than their counterparts in the Northeast, and further study of the geographic differences in pediatric cancer incidence by ethnicity may provide clues to etiology and establish whether this is a real or chance observation (15, 18). We could not study the incidence in children of mixed race because cancer registries do not capture these data, but a birth certificate-cancer registry linkage study in five states reported that patterns of risk tend to mirror those of the minority parent's group (16).

In addition to invasive cancers, non-malignant brain tumors also occur more commonly in the Northeast, but there is wide variation by state, as previously reported (19). Reporting of non-malignant brain tumors to cancer registries began in 2004, and these tumors make up 70% of all brain and CNS tumors (20). It has been shown that case ascertainment for non-malignant brain tumors varies substantially between states and there is wide variation by state in the proportions of these cases that are microscopically confirmed; these proportions are strongly correlated with reported incidence by state, suggesting that flawed case ascertainment may account for these differences (19).

What might underlie the high incidence of pediatric cancer in the Northeast, even after stratifying by race? We know that the incidence of adult cancer is also higher in the Northeast (21) and the reasons for that are also unclear but – as for childhood cancer – likely to be multifactorial. Few strong risk factors for pediatric cancer have been identified. Increasing maternal age at delivery is associated with a higher risk of pediatric cancer in the offspring (22–24); it has been linked to the rising pediatric cancer incidence over time (25), and average maternal age at delivery is higher in the Northeast (26). Higher socioeconomic status (SES) is another risk factor for pediatric cancer (1, 27, 28) that is more prevalent in the Northeast (29, 30); high SES may be a proxy for maternal age and for access to medical care, including testing such as imaging. Increased use of medical imaging may lead to geographic differences in thyroid cancer incidence via enhanced detection of low risk lesions, often as incidental findings (31–34); use of pediatric CT scans is higher with white race, increasing household income, and private health insurance (35–39). However, relative to other regions, there is evidence of less frequent use of CT scans in children in the Northeast (40, 41), even though others cite more frequent use in the Northeast for some adult indications (42, 43). Several studies report excess cancer risk as a result of ionizing radiation exposure during childhood CT scans (32–34, 44). In a large retrospective cohort study, CT scans conducted before age 20 were associated with a 24% excess cancer risk during an average of 9.5 years of follow-up (33), and it has been estimated that the four million pediatric CT scans performed annually in the US will cause more than 4,000 future cancers during the lifespan (44). A host of other possible explanations with varying degrees of evidence have been summarized by Lupo and Spector, including use of chemicals including pesticides and herbicides, pollution, parental smoking and use of recreational drugs and alcohol, maternal obesity and diabetes, preterm birth and birth weight, and possible preventive factors include breast feeding and use of prenatal vitamins (45). High prevalence risk factors for adult cancers in Northeastern states include arsenic in drinking water (46); radon (47); and woodsmoke due to use of wood-based fuels in the home (48), but the evidence supporting causal associations between these factors and pediatric cancer is weak (49–52). Although the Northeast tends to rank well on various EPA pollution metrics (53), the number of EPA National Priorities List (NPL) sites per capita is higher in some areas of the Northeast compared to other regions (54), and examples of pollution in specific areas have raised concerns about possible cancer risks, although epidemiologic studies often have difficulty identifying specific causal associations (55–59). However, individual level data in a large population-based sample would be needed to elucidate the causes of excess pediatric cancer risk in the Northeast, to identify modifiable risk factors and exposure reduction strategies that could be targeted by public health and environmental health interventions.

Strengths of the study include the use of national, population-based cancer registry surveillance data that has undergone annual scrutiny for quality (5, 60), the inclusion of all Northeastern states and their race/ethnicity data, and the use of rigorous statistical methods to compare the Northeast with its constituent states and with other regions or the country as a whole within race-specific strata. Restriction to first primary cancers avoids the potential problem that a first childhood cancer increases the risk of subsequent cancers, which in turn would tend to exaggerate any differences between states or regions with lower and higher incidence of first primaries. Limitations include the exclusion of data from Kansas, Nevada and from 2003 for Mississippi and Tennessee; uncertainty relating to data quality for nonmalignant brain tumor reporting; and lack of information about mixed race/ethnicity.

In conclusion, the incidence of pediatric cancer in the Northeast is higher than the rest of the United States overall, and when race is taken into account. There is no evidence of any general trends towards higher rates in any states within the Northeast. Regional differences in incidence merit further exploration to identify potentially modifiable risk factors.

J.R. Rees reports other support from New Hampshire Department of Health & Human Services during the conduct of the study. K. Craver reports other support from State of New Hampshire during the conduct of the study. M.O. Celaya reports other support from New Hampshire Department of Health & Human Services during the conduct of the study. J.L. Peacock reports other support from New Hampshire Department of Health and Human Services during the conduct of the study. No disclosures were reported by the other authors.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of the New Hampshire Department of Environmental Services (DES), the New Hampshire Department of Health and Human Services (DHHS), or the Centers for Disease Control and Prevention (CDC).

J.R. Rees: Conceptualization, resources, supervision, funding acquisition, visualization, methodology, writing–original draft, project administration, writing–review and editing. J.E. Weiss: Conceptualization, formal analysis, validation, visualization, methodology, writing–original draft, writing–review and editing. B.L. Riddle: Conceptualization, resources, methodology, writing–review and editing. K. Craver: Visualization, methodology, writing–review and editing. M.S. Zens: Visualization, methodology, writing–review and editing. M.O. Celaya: Investigation, methodology, writing–review and editing. J.L. Peacock: Conceptualization, formal analysis, supervision, visualization, methodology, writing–original draft, writing–review and editing.

These analyses used NAACCR's Cancer in North America data referenced below (4). Support for cancer registries is provided by the state, province, or territory in which the registry is located. In the US, registries also participate in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program or the Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR) or both. We thank the New Hampshire Drinking Water and Ground Water Trust Fund for funding this study. The New Hampshire State Cancer Registry is supported in part by the Centers for Disease Control and Preventions (CDC) National Program of Cancer Registries (NPCR) through cooperative agreement NU58DP006298 awarded to the New Hampshire Department of Health and Human Services, Division of Public Health Services, Bureau of Public Health Statistics & Informatics, Health Statistics and Data Management Section. This project was supported in part by the Centers for Disease Control and Preventions (CDC) National Program of Cancer Registries (NPCR) cooperative agreement NU58DP006298 awarded to the New Hampshire Department of Health and Human Services, Division of Public Health Services, Bureau of Disease Control and Health Statistics, Health Statistics and Data Management Section (W. Hammond, PI). The New Hampshire State Registry is funded through a contract awarded to the Trustees of Dartmouth College (J.R. Rees, PI) and this project was funded by the New Hampshire Drinking Water and Ground Water Trust Fund through an amendment to the contract (J.R. Rees, PI).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).

1.
Siegel
DA
,
Li
J
,
Henley
SJ
,
Wilson
RJ
,
Lunsford
NB
,
Tai
E
, et al
.
Geographic Variation in Pediatric Cancer Incidence - United States, 2003–2014
.
MMWR Morb Mortal Wkly Rep
2018
;
67
:
707
13
.
2.
Pediatric Seacoast Cancer Cluster Investigation: A Summary of Investigation Findings as of April 30, 2017: State of New Hampshire, Department of Health and Human Services, Division of Public Health Services
;
2017
.
Available from
: https://www.dhhs.nh.gov/sites/g/files/ehbemt476/files/documents/2021-11/ped-cancer-cluster-summary.pdf.
3.
Investigation of Rhabdomyosarcoma (RMS) Cases in the Rye Area: New Hampshire Department of Health and Human Services, Division of Public Health Services
;
2016
.
Available from
: https://www.dhhs.nh.gov/sites/g/files/ehbemt476/files/documents/2021-11/rhabdomyosarcoma2016.pdf.
4.
SEER*Stat Database: NAACCR Incidence Data - CiNA Analytic File, 1995–2017, for NHIAv2 Origin, Standard File, Rees (20-07) - Revaluation of MMWR Geo Variation of Pediatric Cancer (which includes data from CDC's National Program of Cancer Registries (NPCR), CCCR's Provincial and Territorial Registries, and the NCI's Surveillance, Epidemiology and End Results (SEER) Registries), certified by the North American Association of Central Cancer Registries (NAACCR) as meeting high-quality incidence data standards for the specified time periods, submitted December 2019
.
NAACCR
2021
.
Available from
: https://www.naaccr.org/cina-research/.
5.
Cancer in North America CiNA Data Products
;
2018
.
Available from:
https://www.naaccr.org/cina-data-products-overview/.
6.
SEER*Stat Software, Version 8.3.9 - March 15, 2021
.
National Cancer Institute
;
2021
.
Available from:
www.seer.cancer.gov/seerstat.
7.
CiNA Public Use Dataset
.
North American Association of Central Cancer Registries
;
2021
.
Available from:
https://www.naaccr.org/cina-public-use-data-set/.
8.
NAACCR Guideline for Enhancing Hispanic-Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]
.
Springfield, IL
:
North American Association of Central Cancer Registries
;
2011
.
Available from
: https://www.naaccr.org/wp-content/uploads/2016/11/NHIA_v2_2_1_09122011.pdf.
9.
Available Race Variables
.
National Cancer Institute
;
2021
.
Available from
https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/.
10.
Copeland
G
,
Lake
A
,
Firth
R
,
Wohler
B
,
Wu
XC
,
Schymura
M
,
Hofferkamp
J
,
Sherman
R
,
Kohler
B
(eds).
Cancer in North America: 2009–2013. Volume One: Combined Cancer Incidence for the United States, Canada and North America
.
Springfield, IL
:
North American Association of Central Cancer Registries, Inc
.;
2016
.
11.
Steliarova-Foucher
E
,
Stiller
C
,
Lacour
B
,
Kaatsch
P
.
International Classification of Childhood Cancer, third edition
.
Cancer
2005
;
103
:
1457
67
.
12.
International classification of diseases for oncology (ICD-O) –3rd edition, 1st revision
:
World Health Organization
;
2013
.
Available from
: https://apps.who.int/iris/handle/10665/96612.
13.
Morris
JK
,
Tan
J
,
Fryers
P
,
Bestwick
J
.
Evaluation of stability of directly standardized rates for sparse data using simulation methods
.
Popul Health Metr
2018
;
16
:
19
.
14.
Tiwari
RC
,
Clegg
LX
,
Zou
Z
.
Efficient interval estimation for age-adjusted cancer rates
.
Stat Methods Med Res
2006
;
15
:
547
69
.
15.
Yamamoto
JF
,
Goodman
MT
.
Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002
.
Cancer Causes Control
2008
;
19
:
379
90
.
16.
Chow
EJ
,
Puumala
SE
,
Mueller
BA
,
Carozza
SE
,
Fox
EE
,
Horel
S
, et al
.
Childhood cancer in relation to parental race and ethnicity: a 5-state pooled analysis
.
Cancer
2010
;
116
:
3045
53
.
17.
Duncan
MH
,
Wiggins
CL
,
Samet
JM
,
Key
CR
.
Childhood cancer epidemiology in New Mexico's American Indians, Hispanic whites, and non-Hispanic whites, 1970–82
.
J Natl Cancer Inst
1986
;
76
:
1013
8
.
18.
Miller
KD
,
Fidler-Benaoudia
M
,
Keegan
TH
,
Hipp
HS
,
Jemal
A
,
Siegel
RL
.
Cancer statistics for adolescents and young adults, 2020
.
CA Cancer J Clin
2020
;
70
:
443
59
.
19.
Li
XR
,
Kruchko
C
,
Wu
XC
,
Hsieh
MC
,
Andrews
PA
,
Huang
B
, et al
.
Are benign and borderline brain tumors underreported?
J Registry Manag
2016
;
43
:
187
94
.
20.
Ostrom
QT
,
Patil
N
,
Cioffi
G
,
Waite
K
,
Kruchko
C
,
Barnholtz-Sloan
JS
.
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017
.
Neuro Oncol
2020
;
22
:
iv1
iv96
.
21.
U.S. Cancer Statistics Working Group
.
U.S. Cancer Statistics Data Visualizations Tool, based on 2020 submission data (1999–2018): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute
;
2021
.
Available from
: https://www.cdc.gov/cancer/uscs/dataviz/index.htm.
22.
Panagopoulou
P
,
Skalkidou
A
,
Marcotte
E
,
Erdmann
F
,
Ma
X
,
Heck
JE
, et al
.
Parental age and the risk of childhood acute myeloid leukemia: results from the Childhood Leukemia International Consortium
.
Cancer Epidemiol
2019
;
59
:
158
65
.
23.
Petridou
ET
,
Georgakis
MK
,
Erdmann
F
,
Ma
X
,
Heck
JE
,
Auvinen
A
, et al
.
Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium
.
Eur J Epidemiol
2018
;
33
:
965
76
.
24.
Johnson
KJ
,
Carozza
SE
,
Chow
EJ
,
Fox
EE
,
Horel
S
,
McLaughlin
CC
, et al
.
Parental age and risk of childhood cancer: a pooled analysis
.
Epidemiology
2009
;
20
:
475
83
.
25.
Kehm
RD
,
Osypuk
TL
,
Poynter
JN
,
Vock
DM
,
Spector
LG
.
Do pregnancy characteristics contribute to rising childhood cancer incidence rates in the United States?
Pediatr Blood Cancer
2018
;
65
.
26.
Bui
Q
,
Miller
CC
.
The age that women have babies: how ag divides America
.
New York Times;
2018
.
Available from
: https://www.nytimes.com/interactive/2018/08/04/upshot/up-birth-age-gap.html.
27.
Francis
SS
,
Wang
R
,
Enders
C
,
Prado
I
,
Wiemels
JL
,
Ma
X
, et al
.
Socioeconomic status and childhood central nervous system tumors in California
.
Cancer Causes Control
2021
;
32
:
27
39
.
28.
Gradel
KO
,
Kaerlev
L
.
Antibiotic use from conception to diagnosis of child leukaemia as compared to the background population: A nested case-control study
.
Pediatr Blood Cancer
2015
;
62
:
1155
61
.
29.
Poverty in the United States: Percentage of people in poverty by state: 2015
.
United States Census Bureau
;
2016
.
Available from:
https://www.census.gov/library/visualizations/2016/comm/cb16-158_poverty_map.html.
30.
Singh
GK
,
Miller
BA
,
Hankey
BF
,
Feuer
EJ
,
Pickle
LW
.
Changing area socioeconomic patterns in U.S. cancer mortality, 1950–1998: Part I–all cancers among men
.
J Natl Cancer Inst
2002
;
94
:
904
15
.
31.
Lim
H
,
Devesa
SS
,
Sosa
JA
,
Check
D
,
Kitahara
CM
.
Trends in thyroid cancer incidence and mortality in the United States, 1974–2013
.
JAMA
2017
;
317
:
1338
48
.
32.
Abalo
KD
,
Rage
E
,
Leuraud
K
,
Richardson
DB
,
Le Pointe
HD
,
Laurier
D
, et al
.
Early life ionizing radiation exposure and cancer risks: systematic review and meta-analysis
.
Pediatr Radiol
2021
;
51
:
45
56
.
33.
Mathews
JD
,
Forsythe
AV
,
Brady
Z
,
Butler
MW
,
Goergen
SK
,
Byrnes
GB
, et al
.
Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians
.
BMJ
2013
;
346
:
f2360
.
34.
Pearce
MS
,
Salotti
JA
,
Little
MP
,
McHugh
K
,
Lee
C
,
Kim
KP
, et al
.
Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study
.
Lancet
2012
;
380
:
499
505
.
35.
Fahimi
J
,
Herring
A
,
Harries
A
,
Gonzales
R
,
Alter
H
.
Computed tomography use among children presenting to emergency departments with abdominal pain
.
Pediatrics
2012
;
130
:
e1069
75
.
36.
Mannix
R
,
Bourgeois
FT
,
Schutzman
SA
,
Bernstein
A
,
Lee
LK
.
Neuroimaging for pediatric head trauma: do patient and hospital characteristics influence who gets imaged?
Acad Emerg Med
2010
;
17
:
694
700
.
37.
Marin
JR
,
Rodean
J
,
Hall
M
,
Alpern
ER
,
Aronson
PL
,
Chaudhari
PP
, et al
.
Racial and ethnic differences in emergency department diagnostic imaging at US Children's Hospitals, 2016–2019
.
JAMA Netw Open
2021
;
4
:
e2033710
.
38.
Marin
JR
,
Wang
L
,
Winger
DG
,
Mannix
RC
.
Variation in computed tomography imaging for pediatric injury-related emergency visits
.
J Pediatr
2015
;
167
:
897
904
.
39.
Natale
JE
,
Joseph
JG
,
Rogers
AJ
,
Mahajan
P
,
Cooper
A
,
Wisner
DH
, et al
.
Cranial computed tomography use among children with minor blunt head trauma: association with race/ethnicity
.
Arch Pediatr Adolesc Med
2012
;
166
:
732
7
.
40.
Lodwick
DL
,
Cooper
JN
,
Lawrence
AE
,
Kelleher
KJ
,
Minneci
PC
,
Deans
KJ
.
Factors affecting emergency department computed tomography use in children
.
J Surg Res
2019
;
241
:
294
301
.
41.
Tasian
GE
,
Pulido
JE
,
Keren
R
,
Dick
AW
,
Setodji
CM
,
Hanley
JM
, et al
.
Use of and regional variation in initial CT imaging for kidney stones
.
Pediatrics
2014
;
134
:
909
15
.
42.
Balthazar
P
,
Sadigh
G
,
Hughes
D
,
Rosenkrantz
AB
,
Hanna
T
,
Duszak
R
Jr
.
Increasing use, geographic variation, and disparities in emergency department CT for suspected urolithiasis
.
J Am Coll Radiol
2019
;
16
:
1547
53
.
43.
Welch
HG
,
Skinner
JS
,
Schroeck
FR
,
Zhou
W
,
Black
WC
.
Regional variation of computed tomographic imaging in the United States and the risk of nephrectomy
.
JAMA Intern Med
2018
;
178
:
221
7
.
44.
Miglioretti
DL
,
Johnson
E
,
Williams
A
,
Greenlee
RT
,
Weinmann
S
,
Solberg
LI
, et al
.
The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk
.
JAMA Pediatr
2013
;
167
:
700
7
.
45.
Lupo
PJ
,
Spector
LG
.
Cancer progress and priorities: childhood cancer
.
Cancer Epidemiol Biomarkers Prev
2020
;
29
:
1081
94
.
46.
Ayotte
JD
,
Montgomery
DL
,
Flanagan
SM
,
Robinson
KW
.
Arsenic in groundwater in eastern New England: occurrence, controls, and human health implications
.
Environ Sci Technol
2003
;
37
:
2075
83
.
48.
Rokoff
LB
,
Koutrakis
P
,
Garshick
E
,
Karagas
MR
,
Oken
E
,
Gold
DR
, et al
.
Wood stove pollution in the developed world: a case to raise awareness among pediatricians
.
Curr Probl Pediatr Adolesc Health Care
2017
;
47
:
123
41
.
49.
Greenop
KR
,
Hinwood
AL
,
Fritschi
L
,
Scott
RJ
,
Attia
J
,
Ashton
LJ
, et al
.
Vehicle refuelling, use of domestic wood heaters and the risk of childhood brain tumours: results from an Australian case-control study
.
Pediatr Blood Cancer
2015
;
62
:
229
34
.
50.
Engel
A
,
Lamm
SH
.
Arsenic exposure and childhood cancer–a systematic review of the literature
.
J Environ Health
2008
;
71
:
12
6
.
51.
Moore
LE
,
Lu
M
,
Smith
AH
.
Childhood cancer incidence and arsenic exposure in drinking water in Nevada
.
Arch Environ Health
2002
;
57
:
201
6
.
52.
Lu
Y
,
Liu
L
,
Chen
Q
,
Wei
J
,
Cao
G
,
Zhang
J
.
Domestic radon exposure and risk of childhood leukemia: a meta-analysis
.
J BUON
2020
;
25
:
1035
41
.
53.
Toxics Release Inventory Analysis 2019: Environmental Protection Agency
;
2021
.
Available from
: https://www.epa.gov/sites/production/files/2021-01/documents/section_5._regional_profiles.pdf.
54.
Superfund National Priorities List (NPL)
.
EPA
,
2021
.
Available from:
https://www.epa.gov/superfund/superfund-national-priorities-list-npl.
55.
Panikkar
B
,
Lemmond
B
,
Allen
L
,
DiPirro
C
,
Kasper
S
.
Making the invisible visible: results of a community-led health survey following PFAS contamination of drinking water in Merrimack, New Hampshire
.
Environ Health
2019
;
18
:
79
.
56.
Daly
ER
,
Chan
BP
,
Talbot
EA
,
Nassif
J
,
Bean
C
,
Cavallo
SJ
, et al
.
Per- and polyfluoroalkyl substance (PFAS) exposure assessment in a community exposed to contaminated drinking water, New Hampshire, 2015
.
Int J Hyg Environ Health
2018
;
221
:
569
77
.
57.
Durant
JL
,
Chen
J
,
Hemond
HF
,
Thilly
WG
.
Elevated incidence of childhood leukemia in Woburn, Massachusetts: NIEHS Superfund Basic Research Program searches for causes
.
Environ Health Perspect
1995
;
103
:
93
8
.
58.
Costas
K
,
Knorr
RS
,
Condon
SK
.
A case-control study of childhood leukemia in Woburn, Massachusetts: the relationship between leukemia incidence and exposure to public drinking water
.
Sci Total Environ
2002
;
300
:
23
35
.
59.
Cutler
JJ
,
Parker
GS
,
Rosen
S
,
Prenney
B
,
Healey
R
,
Caldwell
GG
.
Childhood leukemia in Woburn, Massachusetts
.
Public Health Rep
1986
;
101
:
201
5
.
60.
Data Quality Assessments and Evaluations
.
North American Association of Central Cancer Registries
;
2021
.
Available from:
https://www.naaccr.org/data-quality-assessments-and-evaluations/.

Supplementary data